Construction of Carbiotix first production site at FoodHills ramps up
Carbiotix (publ) ("Carbiotix" or “the Company”) today announces that construction activities of its first production site capable of producing up to 10 tons of CarbiAXOS per year will ramp up in August at FoodHills in Bjuv, Sweden, with planned completion by the end of 2021.
Kristofer Cook, CEO for Carbiotix, comments
“I am very pleased to announce that we soon will ramp up the construction activities of our first production site at FoodHills in Bjuv, Sweden, capable of producing up to 10 tons of CarbiAXOS per year. Demolition work is now nearly completed of the former research and development site of Findus. After a recent site inspection and alignment meeting between site engineering teams, work to construct our site is slated to commence in August, with a planned completion of the first phase by the end of 2021.
The construction schedule was impacted by the comprehensive evaluation of the new production enzyme which was recently completed. However, we used this time to improve the flexibility and utility of our first site. This includes the ability to use the current floor plan to expand production to up to 100 tons per year during 2022, allocate space for research and development activities of new prebiotic products, and outsource space to complementary development projects.
Overall, I am extremely pleased with the progress to date and our partnership with FoodHills as a property owner. The current site will serve our core production needs in the short to medium term, become our primary research and development site in the long term, and provide a template for further expansion on the FoodHills property as we grow our production to meet customer demand. I look forward to providing progress updates in the second half of the year, along with a more defined road map of the products we will launch from the FoodHills location."
This is information that Carbiotix AB is obliged to make public according to the EU Market Abuse Regulation (MAR). The information was made publicly available by the Company’s contact person set out below on 7 July 2021.
This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios as described in this press release.
For further information:
Kristofer Cook, CEO
Tel: +46 (0)708-796580
Carbiotix AB (CRBX) (www.carbiotix.com) is an award-winning biotechnology company pioneering microbiome healthcare through a range of cost-effective gut health testing services and a portfolio of microbiome modulators covering prebiotic ingredients, medical foods and therapeutics.